Cargando…

Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis

BACKGROUND: Precision and matched cancer medicine has the potential to complement the existing biomarker approaches in cancer treatment. However, despite their promising potential, certain negative results have highlighted their limitations in molecular biology-driven treatment strategies. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hibino, Y., Ito, M., Satake, T., Kondo, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207218/ https://www.ncbi.nlm.nih.gov/pubmed/34118770 http://dx.doi.org/10.1016/j.esmoop.2021.100187

Ejemplares similares

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2016)

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2017)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’
por: Grössmann, N., et al.
Publicado: (2021)

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016)

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
por: Roitberg, F., et al.
Publicado: (2023)

Clinical Trials in Oncology and Defining Benefit
por: Sorscher, Steven
Publicado: (2017)

Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
por: Müller, B., et al.
Publicado: (2022)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
por: Cusano, Ellen, et al.
Publicado: (2021)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020)

Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
por: Rassy, Elie, et al.
Publicado: (2023)

Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
por: Pichler, M., et al.
Publicado: (2021)

Association between control group therapy and magnitude of clinical benefit of cancer drugs
por: Molto, Consolacion, et al.
Publicado: (2022)

The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
por: van Tilburg, Cornelis M., et al.
Publicado: (2021)

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
por: Rodriguez, Adela, et al.
Publicado: (2021)

Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process
por: Wolf, I., et al.
Publicado: (2022)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

The Academy of the European Federation of Clinical Chemistry and Laboratory Medicine – benefits and opportunities
por: Simundic, Ana-Maria
Publicado: (2021)

The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology
por: Takesh, Mustafa
Publicado: (2012)

Translating “Big Data” in Oncology for Clinical Benefit: Progress or Paralysis
por: Barker, Anna D., et al.
Publicado: (2022)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
por: Radovich, Milan, et al.
Publicado: (2016)

Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia
por: Seymour, Erlene K., et al.
Publicado: (2017)

Benefits of Dental Societies
por: Barber, W. A.
Publicado: (1903)

Changing the landscape of European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic
por: Pavlidis, Nicholas, et al.
Publicado: (2022)

Comparing Lifestyle Modifications and the Magnitude of Their Associated Benefit on Cancer Mortality
por: Dougherty, Timothy P., et al.
Publicado: (2023)

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
por: Everest, Louis, et al.
Publicado: (2019)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
por: Cobain, Erin F., et al.
Publicado: (2021)

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
por: Kirkwood, John M., et al.
Publicado: (2012)

Individual differences in working memory capacity are unrelated to the magnitudes of retrocue benefits
por: Ye, Chaoxiong, et al.
Publicado: (2021)

The benefits of SOLID in software development
por: AGUDO SANTOS, Ruben
Publicado: (2015)

Further evidence of clinical benefit associated with participation in phase I oncology trials
por: Markman, M
Publicado: (2008)

Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)

Benefits of Dental Society Meetings
por: Delzell, D. E.
Publicado: (1896)

Cannot write session to /tmp/vufind_sessions/sess_coiblr01iinib076c2r88f6mk6